Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

GMX1777 is a prodrug form of the nicotinamide phosphoribosyltransferase (Nampt) inhibitor CHS-828 (Item No. 11021).1 Intravenous administration of GMX1777 (75 and 150 mg/kg) reduces NAD+ levels in tumors, but not muscle tissue, in a DMS 273 lung cancer mouse xenograft model. GMX1777 (50 mg/kg per day), in combination with radiation, decreases tumor diameter and microvessel density in C666-1 nasopharyngeal and FaDu head and neck squamous cell carcinoma (HNSCC) mouse xenograft models.2
WARNING This product is not for human or veterinary use.
1. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 20(5), 346-354 (2009).
2. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin. Cancer Res. 16(3), 898-911 (2010).